Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 13/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 13/20 | 0.35 |
| ▸ | NNMT | P40261 | 1/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4015307 | 0.91 | PDE4A (0.36) | POLBTDP1MTNR1AMTNR1BNNMT | |
| SCHEMBL6935324 | 0.80 | NNMT (0.38) | POLBTDP1MTNR1AMTNR1BNNMT | |
| SCHEMBL2081951 | 0.80 | POLB (0.35) | POLBTDP1MTNR1AMTNR1BNNMT | |
| SCHEMBL7899408 | 0.79 | PDE4A (0.41) | POLBTDP1MTNR1AMTNR1BNNMT | |
| SCHEMBL29222820 | 0.78 | TXNRD1 (0.36) | POLBTDP1MTNR1AMTNR1BNNMT | |
| SCHEMBL20303769 | 0.76 | CYP11B2 (0.37) | POLBTDP1NNMTTXNRD1 | |
| SCHEMBL30985306 | 0.76 | TDP1 (0.58) | POLBTDP1MTNR1AMTNR1BNNMT | |
| SCHEMBL11039067 | 0.75 | KDM4E (0.48) | — | |
| SCHEMBL19147836 | 0.74 | MTNR1A (0.39) | POLBTDP1MTNR1AMTNR1BNNMT | |
| SCHEMBL4009723 | 0.73 | ALDH1A1 (0.34) | POLBTDP1MTNR1AMTNR1BNNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115611925-B | HPK1 inhibitors and uses thereof | 轩竹生物科技股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| CN-115611925-A | HPK1 inhibitors and uses thereof | 轩竹生物科技股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-12-01 | — | — | US | disclosed |
| US-11390623-B2 | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | PFIZER INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-3402796-B1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS | PFIZER (US) | 2020-11-18 | — | — | EP | disclosed |
| EP-3402796-B1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS | PFIZER (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200157098-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS | PFIZER (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200157098-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS | PFIZER (US) | 2020-05-21 | — | — | US | disclosed |
| US-10590128-B2 | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | PFIZER, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
| US-20190047997-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | PFIZER INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190047997-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | PFIZER INC. (US) | 2019-02-14 | — | — | US | disclosed |
| WO-2017122116-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | PFIZER INC. (US) | 2017-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390623-B2 | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | DRD3, DRD2, DRD4 | POLB 3198/4885TDP1 1766/4885MTNR1A 332/4885 |
| US-20200157098-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINE DOPAMINE D3 LIGANDS | DRD3, DRD2, DRD4 | POLB 3198/4885TDP1 1766/4885MTNR1A 332/4885 |
| US-10590128-B2 | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | DRD3, DRD2, DRD4 | POLB 3198/4885TDP1 1766/4885MTNR1A 332/4885 |
| US-20220380358-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | BACE1, BACE2, BCHE | POLB 3177/4885TDP1 622/4885MTNR1A 235/4885 |
| US-20190047997-A1 | 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS | DRD3, DRD2, DRD4 | POLB 3198/4885TDP1 1766/4885MTNR1A 332/4885 |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | POLB 3177/4885TDP1 622/4885MTNR1A 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.